Zydus Lifesciences gets EIR for Ankleshwar API manufacturing facility from USFDA

12 Jun 2025 Evaluate

Zydus Lifesciences has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for the inspection conducted at its API manufacturing facility located at Ankleshwar. This facility underwent an inspection from March 10, 2025 to March 14, 2025 and the inspection has been classified as No Action Indicated (NAI). The USFDA has concluded that this inspection is ‘closed’.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

Zydus Lifesciences Share Price

904.00 -7.50 (-0.82%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×